Generalized Myasthenia Gravis in Argentina: serological profile and clinical characteristics. A hospital-based study

AGUIRRE FLORENCIA; MARIELA L. PAZ; CORES V; JULIANA LEONI; ANDRÉS VILLA

Washington

Congreso; American Academy of Neurology 67th Annual Meeting; 2015

American Academy of Neurology

Objective: To study the serological status amongst generalized Myasthenia Gravis (MG) patients and their relationship with clinical features and the outcome of the disease in a hospital-based study from Buenos Aires, Argentina. Background: Acetylcholine receptor antibody (AChR-Ab) is the most common antibody found in MG. In AChR-Ab negative patient, a percentage which varies in different series, presents anti-muscle specific kinase antibodies (MuSK-Ab), anti-LPR4 antibodies, or are considered double seronegative patients. Design/Methods: We retrospectively reviewed the medical records of patients affected by generalized MG attending at Ramos Mejia Hospital in Buenos Aires City, and related their serogical status with clinical characteristics of MG. Results: Amongst 98 generalized MG patients, 82 were AChR-Ab positive(83.7%). 4/12(33.3%) AChR-Ab negative patients were MuSK-Ab positive and 8/12 double seronegative-MG. No differences were found related to gender, age at onset and autoimmmune comorbidity between the three groups. Clinical features showed an initial ocular involvement more frequently in AChR-Ab negative groups: 75%(3/4) in Musk-Ab positive, 87.5%(7/8) in double seronegative-MG and 48.1%(39/81) in AChR-Ab positive MG(p